UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 3, 2016

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At May 9, 2016, 6,064,849,361 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended April 3, 2016 and March 29, 2015

Condensed Consolidated Statements of Comprehensive Income for the three months ended April 3, 2016 and March 29, 2015

Condensed Consolidated Balance Sheets as of April 3, 2016 and December 31, 2015

Condensed Consolidated Statements of Cash Flows for the three months ended April 3, 2016 and March 29, 2015

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

38

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

39

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

89

Item 4.

Controls and Procedures

89

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

90

Item 1A.

Risk Factors

90

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

91

Item 3.

Defaults Upon Senior Securities

91

Item 4.

Mine Safety Disclosures

91

Item 5.

Other Information

91

Item 6.

Exhibits

92

Signature

93

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

April 3,

2016

March 29,

2015

Revenues

13,005

10,864

Costs and expenses:

Cost of sales(a)

2,851

1,838

Selling, informational and administrative expenses(a)

3,385

3,104

Research and development expenses(a)

1,731

1,885

Amortization of intangible assets

1,006

940

Restructuring charges and certain acquisition-related costs

141

60

Other (income)/deductions net

330

(46

Income from continuing operations before provision for taxes on income

3,561

3,082

Provision for taxes on income

535

706

Income from continuing operations

3,026

2,376

Discontinued operations net of tax

Net income before allocation to noncontrolling interests

3,026

2,381

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

3,016

2,376

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.49

0.38

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.49

0.38

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.49

0.38

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.49

0.38

Weighted-average shares basic

6,150

6,203

Weighted-average shares diluted

6,214

6,292

Cash dividends paid per common share

0.30

0.28

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill:Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

April 3,

2016

March 29,

2015

Net income before allocation to noncontrolling interests

3,026

2,381

Foreign currency translation adjustments, net

67

(1,308

67

(1,308

Unrealized holding losses on derivative financial instruments, net

(273

(315

Reclassification adjustments for realized (gains)/losses(a)

(339

234

(612

(82

Unrealized holding gains/(losses) on available-for-sale securities, net

129

(328

Reclassification adjustments for realized losses(a)

209

247

339

(81

Benefit plans: actuarial gains, net

32

Reclassification adjustments related to amortization(b)

139

136

Reclassification adjustments related to settlements, net(b)

26

40

Other

38

158

203

365

Benefit plans: prior service costs and other, net

(1

Reclassification adjustments related to amortization(b)

(41

(35

Reclassification adjustments related to curtailments, net(b)

(6

(10

Other

(42

(46

Other comprehensive loss, before tax

(44

(1,152

Tax provision/(benefit) on other comprehensive loss(c)

(41

105

Other comprehensive loss before allocation to noncontrolling interests

(4

(1,257

Comprehensive income before allocation to noncontrolling interests

3,022

1,124

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(10

Comprehensive income attributable to Pfizer Inc.

3,019

1,134

(a)

Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(b)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(c)

See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Loss.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

April 3,

2016

December 31,

2015

(Unaudited)

Assets

Cash and cash equivalents

2,561

3,641

Short-term investments

16,882

19,649

Trade accounts receivable, less allowance for doubtful accounts: 2016 $649; 2015 $384

9,033

8,176

Inventories

7,578

7,513

Current tax assets

2,888

2,662

Other current assets

2,355

2,163

Total current assets

41,298

43,804

Long-term investments

14,146

15,999

Property, plant and equipment, less accumulated depreciation: 2016 $14,002; 2015 $13,502

13,584

13,766

Identifiable intangible assets, less accumulated amortization

39,602

40,356

Goodwill

48,558

48,242

Noncurrent deferred tax assets and other noncurrent tax assets

1,738

1,794

Other noncurrent assets

4,003

3,420

Total assets

162,929

167,381

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

11,546

10,159

Trade accounts payable

3,125

3,620

Dividends payable

1,852

Income taxes payable

920

418

Accrued compensation and related items

1,725

2,359

Other current liabilities

11,419

10,990

Total current liabilities

28,735

29,399

Long-term debt

27,824

28,740

Pension benefit obligations, net

5,264

6,310

Postretirement benefit obligations, net

1,980

1,809

Noncurrent deferred tax liabilities

26,547

26,877

Other taxes payable

4,053

3,992

Other noncurrent liabilities

5,180

5,257

Total liabilities

99,582

102,384

Commitments and Contingencies

Preferred stock

26

26

Common stock

460

459

Additional paid-in capital

81,443

81,016

Treasury stock

(84,313

(79,252

Retained earnings

74,971

71,993

Accumulated other comprehensive loss

(9,520

(9,522

Total Pfizer Inc. shareholders equity

63,068

64,720

Equity attributable to noncontrolling interests

279

278

Total equity

63,347

64,998

Total liabilities and equity

162,929

167,381

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

April 3,

2016

March 29,

2015

Operating Activities

Net income before allocation to noncontrolling interests

3,026

2,381

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

1,425

1,260

Asset write-offs and impairments

146

11

Deferred taxes from continuing operations

(204

(41

Share-based compensation expense

143

162

Benefit plan contributions in excess of expense

(853

(874

Other adjustments, net

229

(336

Other changes in assets and liabilities, net of acquisitions and divestitures

(2,261

(1,883

Net cash provided by operating activities

1,651

680

Investing Activities

Purchases of property, plant and equipment

(301

(239

Purchases of short-term investments

(3,489

(7,546

Proceeds from redemptions/sales of short-term investments

7,922

10,702

Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less

493

5,243

Purchases of long-term investments

(1,308

(3,150

Proceeds from redemptions/sales of long-term investments

1,142

1,937

Acquisitions of businesses, net of cash acquired

(110

(678

Acquisitions of intangible assets

(7

Other investing activities, net

330

Net cash provided by investing activities

4,355

6,592

Financing Activities

Proceeds from short-term borrowings

682

1,999

Principal payments on short-term borrowings

(1,350

Net proceeds from short-term borrowings with original maturities of three months or less

1,724

863

Principal payments on long-term debt

(1,536

(2,998

Purchases of common stock

(5,000

(6,000

Cash dividends paid

(1,854

(1,758

Proceeds from exercise of stock options

296

794

Other financing activities, net

25

122

Net cash used in financing activities

(7,014

(6,978

Effect of exchange-rate changes on cash and cash equivalents

(73

(74

Net increase/(decrease) in cash and cash equivalents

(1,080

220

Cash and cash equivalents, beginning

3,641

3,343

Cash and cash equivalents, end

2,561

3,563

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

518

372

Interest

382

332

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the United States (U.S.) Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.

The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 28, 2016 and February 22, 2015. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended April 3, 2016 and March 29, 2015.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Annual Report on Form 10-K.

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets, Other noncurrent assets, Short-term borrowings, including current portion of long-term debt and Long-term debt, and in the condensed consolidated statement of cash flows for the three months ended March 29, 2015, we performed certain reclassifications to conform to the current presentation of Proceeds from short-term borrowings for debt issuance costs in accordance with the adoption of a new accounting standard (for additional information, see Note 1B). Certain prior period reclassifications were made to the Global Established Pharmaceutical (GEP) segment operating results to conform to the current period presentation for certain organizational changes impacting GEP in 2016. For additional information, see Note 13.

On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan plc (Allergan) entered into on November 22, 2015 was terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which falls into Pfizer s second fiscal quarter), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan s expenses associated with the terminated transaction. Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement or the transactions contemplated thereby.

On September 3, 2015, we completed our acquisition of Hospira, Inc. (Hospira) and, commencing from the acquisition date, our financial statements reflect the assets, liabilities. operating results and cash flows of Hospira. As a result, legacy Hospira operations are reflected in our results of operations, GEP s operating results, and cash flows for the first quarter of 2016, but not for the first quarter of 2015. Legacy Hospira assets and liabilities are reflected in our balance sheets as of April 3, 2016 and December 31, 2015.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

B. Adoption of New Accounting Standards

We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of April 3, 2016, debt issuance costs are $76 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ($1 million) and Long-term debt ($75 million). In the December 31, 2015 condensed consolidated balance sheet, we have reclassified debt issuance costs of $79 million ($1 million from Other current assets and $79 million from Other noncurrent assets) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ($1 million) and Long-term debt ($79 million) to conform to the current period presentation. For additional information, see Note 7A.

We adopted a new standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our condensed consolidated financial statements in the first quarter of 2016 from adopting this standard. For additional information, see Note 2A.

We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our condensed consolidated financial statements from adopting this standard.

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Note 2. Acquisitions, Research and Development and Collaborative Arrangements, and Equity-Method Investments

A. Acquisitions

Hospira, Inc. (Hospira)

On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ($15.7 billion, net of cash acquired). Hospira is now a subsidiary of Pfizer. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first quarter of 2016 to the provisional amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(MILLIONS OF DOLLARS)

Amounts Recognized

as of Acquisition Date (as previously reported as of December 31, 2015)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as adjusted)

Working capital, excluding inventories

274

(6

268

Inventories

1,924

(16

1,908

Property, plant and equipment(a)

2,410

(53

2,357

Identifiable intangible assets, excluding in-process research and development(a)

8,270

65

8,335

In-process research and development

995

1,000

Other noncurrent assets

408

(46

362

Long-term debt

(1,928

(1,928

Benefit obligations

(117

(117

Net income tax accounts

(3,394

25

(3,369

Other noncurrent liabilities

(39

(39

Total identifiable net assets

8,803

(25

8,778

Goodwill

7,284

25

7,309

Net assets acquired/total consideration transferred

16,087

16,087

(a)

The measurement period adjustments for Identifiable intangible assets reflect changes in the estimated fair value of acquired finite-lived developed technology rights. The measurement period adjustments for Property, plant and equipment primarily reflect changes in the estimated fair value of acquired buildings and machinery and equipment. The changes in the estimated fair values for identifiable intangible assets and property, plant and equipment are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

The change in the provisional amounts had no material impact on our results of operations.

The following items are subject to change:

Amounts for certain balances included in working capital (excluding inventories), certain investments and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.

Amounts for intangibles, inventory and property, plant and equipment, pending finalization of valuation efforts for acquired intangible assets as well as the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain property, plant and equipment assets.

Amounts for income tax assets, receivables and liabilities, pending the filing of Hospira pre-acquisition tax returns and the receipt of information including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.

The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014:

Unaudited Supplemental Pro Forma Consolidated Results

Three Months Ended

(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA)

March 29,

2015

Revenues

12,039

Net income attributable to Pfizer Inc. common shareholders

2,375

Diluted earnings per share attributable to Pfizer Inc. common shareholders

0.38

The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company s results of operations would have been had the acquisition occurred on January 1, 2014, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors. The unaudited supplemental pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed from Hospira.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The unaudited supplemental pro forma consolidated results reflect the historical financial information of Pfizer and Hospira, adjusted to give effect to the acquisition of Hospira as if it had occurred on January 1, 2014, primarily for the following pre-tax adjustments:

Elimination of Hospira s historical intangible asset amortization expense (approximately $12 million in the first quarter of 2015).

Additional amortization expense (approximately $127 million in the first quarter of 2015) related to the preliminary estimate of the fair value of identifiable intangible assets acquired.

Additional depreciation expense (approximately $22 million in the first quarter of 2015) related to the preliminary estimate of the fair value adjustment to property, plant and equipment (PP&E) acquired.

Adjustment related to the preliminary estimate of the non-recurring fair value adjustment to acquisition-date inventory estimated to have been sold (the addition of $5 million of charges in the first quarter of 2015).

Adjustment to decrease interest expense (approximately $10 million in the first quarter of 2015) related to the fair value adjustment of Hospira debt.

Adjustment for non-recurring acquisition-related costs directly attributable to the acquisition (the elimination of $14 million of charges in the first quarter of 2015), reflecting non-recurring charges incurred by Hospira, which would have been recorded in 2014 under the pro forma assumption that the Hospira acquisition was completed on January 1, 2014. Pfizer did not incur any such charges in the first quarter of 2015.

The above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments related to the preliminary estimate of the fair value adjustment for acquired intangible assets, property, plant and equipment, inventory and debt reflect the statutory tax rates in the various jurisdictions where the adjustments are expected to be incurred. The taxes associated with the elimination of Hospira s historical intangible asset amortization expense and the adjustment for the acquisition-related costs directly attributable to the acquisition were based on the tax rate in the jurisdiction in which the related deductible costs were incurred.

Marketed Vaccines Business of Baxter International Inc. (Baxter)

On December 1, 2014 (which falls in the first fiscal quarter of 2015 for our international operations), we acquired Baxter s portfolio of marketed vaccines for a final purchase price of $648 million. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identifiable intangible assets, primarily consisting of $371 million in Developed technology rights. We also recorded $194 million of Inventories and $12 million in Goodwill. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.

B. Research and Development and Collaborative Arrangements

Research and Development Arrangement with RPI Finance Trust (RPI)

In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI will fund up to $300 million in development costs related to certain Phase III clinical trials of Pfizer s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). If successful and upon approval of Ibrance in the U.S. or certain major markets in the European Union (EU) for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to $250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. RPI s development funding is expected to cover up to 100% of the costs primarily for the applicable clinical trials through 2021. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for the first quarter of 2016 totaled $8.8 million. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when incurred.

Collaboration with Eli Lilly & Company (Lilly)

In October 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

and certain product-related costs. Following the decision by the U.S. Food and Drug Administration (FDA) in March 2015 to lift the partial clinical hold on the tanezumab development program, we received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which is recorded as deferred income in our condensed consolidated balance sheet and is being recognized into Other (income)/deductions net over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015, which will consist of six studies in approximately 7,000 patients across osteoarthritis, chronic low back pain and cancer pain. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones.

Collaboration with OPKO Health, Inc. (OPKO)

We entered into a collaborative agreement with OPKO, which closed in January 2015, to develop and commercialize OPKO s long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. We have received the exclusive license to commercialize hGH-CTP worldwide. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which include Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications, all postmarketing studies, manufacturing and commercialization activities for all indications, and we will lead the manufacturing activities related to product development. In February 2015, we made an upfront payment of $295 million to OPKO, which was recorded in Research and development expenses, and OPKO is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. OPKO is also eligible to receive royalty payments associated with the commercialization of hGH-CTP for Adult GHD, which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to tiered gross profit sharing for both hGH-CTP and our product, Genotropin.

C. Equity-Method Investments

Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)

In the first quarter of 2016, we determined that we had an other-than-temporary decline in the value of Hisun Pfizer, our 49%-owned equity-method investment in China, and, therefore, we recognized a loss of $81 million in Other (income)/deductions net (see Note 4). The decline in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued slowdown in the Chinese economy. As of April 3, 2016, the carrying value of our investment in Hisun Pfizer is $680 million, which is included in Long-term investments.

In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, utilizing a 13.0% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.

Investment in Laborat rio Teuto Brasileiro S.A. (Teuto)

In the first quarter of 2016, we determined that we had an other-than-temporary decline in the value of Teuto, a 40%-owned generics company in Brazil, and, therefore, we recognized a loss of $50 million in Other (income)/deductions net (see Note 4) related to our equity method investment. The decline in value resulted from lower expectations as to the future cash flows to be generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the Brazilian Real.

In valuing our investment in Teuto, we used discounted cash flow techniques, utilizing a 17.5% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We have an option to acquire the remaining 60% of Teuto, and Teuto s shareholders have an option to sell their 60% stake in the company to us. Under the terms of our agreement with Teuto s other shareholders, 2016 is the final year in which the call and put options may be exercised. Our investment in Teuto is accounted for under the equity method due to the significant influence we have over the operations of Teuto through our board representation, minority veto rights and 40% voting interest.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:

In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations.

In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three-year period post-acquisition, we expect to incur costs of approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired in-process research and development rights as described in the Current-Period Key Activities section of Notes to Consolidated Financial Statements Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives in our 2015 Financial Report) associated with the integration of Hospira.

In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives. We have the following initiatives underway associated with these programs:

Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of four sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $400 million associated with prior acquisition activity and costs of approximately $1.0 billion associated with new non-acquisition-related cost-reduction initiatives. Through April 3, 2016, we incurred approximately $357 million and $570 million, respectively, associated with these initiatives.

The 2014 global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support different reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $225 million. Through April 3, 2016, we incurred approximately $219 million associated with this reorganization.

Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $850 million. Through April 3, 2016, we incurred approximately $532 million associated with these initiatives.

The costs expected to be incurred during 2014-2016, of approximately $2.5 billion in total for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.

Current-Period Key Activities

In the first quarter of 2016, we incurred approximately $228 million in cost-reduction and acquisition-related costs (excluding transaction costs) primarily in connection with the acquisition of Hospira and the aforementioned programs, mainly associated with our manufacturing operations.

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:

Three Months Ended

(MILLIONS OF DOLLARS)

April 3,

2016

March 29,

2015

Restructuring charges(a):

Employee terminations

24

31

Asset impairments

Exit costs

Total restructuring charges

30

42

Transaction costs(b)

24

Integration costs(c)

87

13

Restructuring charges and certain acquisition-related costs

141

60

Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(d):

Cost of sales

45

17

Research and development expenses

Total additional depreciation asset restructuring

49

18

Implementation costs recorded in our condensed consolidated statements of income as follows(e):

Cost of sales

43

13

Selling, informational and administrative expenses

12

26

Research and development expenses

Total implementation costs

62

48

Total costs associated with acquisitions and cost-reduction/productivity initiatives

252

127

(a)

In the three months ended April 3, 2016, Employee terminations represent the expected reduction of the workforce by approximately 100 employees, mainly in manufacturing. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.

The restructuring charges for the three months ended April 3, 2016 are associated with the following:

the Global Innovative Pharmaceutical segment (GIP) ($8 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($1 million); the Global Established Pharmaceutical segment (GEP) ($3 million); Worldwide Research and Development and Medical (WRD/M) ($3 million); manufacturing operations ($14 million); and Corporate ($1 million).

The restructuring charges for the three months ended March 29, 2015 are associated with the following:

GIP ($12 million); VOC ($13 million); GEP ($10 million); WRD/M ($12 million); manufacturing operations ($22 million income); and Corporate ($18 million).

(b)

Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which are directly related to the terminated transaction with Allergan.

(c)

Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes, primarily related to the acquisition of Hospira.

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)

Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following table provides the components of and changes in our restructuring accruals:

(MILLIONS OF DOLLARS)

Employee

Termination Costs

Asset

Impairment Charges

Exit Costs

Accrual

Balance, December 31, 2015(a)

1,109

48

1,157

Provision

24

30

Utilization and other(b)

(165

(1

(9

(175

Balance, April 3, 2016(c)

968

43

1,011

(a)

Included in Other current liabilities ($776 million) and Other noncurrent liabilities ($381 million).

(b)

Includes adjustments for foreign currency translation.

(c)

Included in Other current liabilities ($638 million) and Other noncurrent liabilities ($373 million).

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

The following table provides components of Other (income)/deductions net:

Three Months Ended

(MILLIONS OF DOLLARS)

April 3,

2016

March 29,

2015

Interest income(a)

(113

(93

Interest expense

306

309

Net interest expense

193

216

Royalty-related income

(187

(222

Certain legal matters, net(b)

274

Net gains on asset disposals(c)

(9

(175

Certain asset impairments(d)

131

Business and legal entity alignment costs(e)

51

101

Other, net(f)

(122

34

Other (income)/deductions net

330

(46

(a)

Interest income increased in the first quarter of 2016, primarily due to higher investment returns.

(b)

In the first quarter of 2016, primarily includes an accrual for an unresolved legal matter and a settlement related to a patent matter.

(c)

In the first quarter of 2016, primarily includes gains on sales/out-licensing of product and compound rights (approximately $16 million). In the first quarter of 2015, primarily includes gains on sales/out-licensing of product and compound rights (approximately $45 million) and gains on sales of investments in equity securities (approximately $120 million).

(d)

In the first quarter of 2016, represents an impairment loss of $81 million related to Pfizer s 49%-owned equity-method investment with Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun) in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40%-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2C.

(e)

In the first quarter of 2016 and 2015, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.

(f)

In the first quarter of 2016, primarily includes, among other things, income of $116 million from resolution of a contract disagreement.

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

Our effective tax rate for continuing operations was 15.0% for the first quarter of 2016, compared to 22.9% for the first quarter of 2015.

The lower effective tax rate for the first quarter of 2016 in comparison with the same period in 2015 was primarily due to:

benefits related to the final resolution (pending court approval) of an agreement in principle reached in February 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our assessment of the likelihood of prevailing on the technical merits of our tax position;

benefits associated with our Venezuela operations;

an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years with various foreign tax authorities, and the expiration of certain statutes of limitations; as well as

an increase in benefits associated with the U.S. R&D tax credit, which was not in effect in the prior year quarter but was permanently extended on December 18, 2015,

partially offset by:

an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)